Drug
BLI-489 clinical trials
Also written BLI-489.
- studies test it
- 4
- open now
- 0
- in phase 3
- 0
- first study started
- 2009
How studies write it
Studies that test it under each name
Development codes
- BLI-489
- 4
By phase
A phase 1/2 study counts in both.
- Phase 1
- 4
Who runs them
Industry 4 · Other 0
Related medicines
As reviewed, each with the page that says it.
- One of Beta-Lactamase Inhibitors source
Studies
Open first, then newest update. How each study uses BLI-489 is read from its arms, and is right about nine times in ten.
Testing it · 4
- Study Evaluating Single Doses of BLI-489 in Healthy Japanese Male SubjectsCompletedPhase 1Wyeth is now a wholly owned subsidiary of PfizerNCT00854009Written as BLI-489
- Study to Evaluate Whether BLI-489 Can be Safely Tolerated by Healthy Subjects Given Multiple DosesCompletedPhase 1Wyeth is now a wholly owned subsidiary of PfizerNCT00909688Written as BLI-489
- Study Evaluating Single Doses of BLI-489 in Healthy SubjectsCompletedPhase 1Wyeth is now a wholly owned subsidiary of PfizerNCT00820404Written as BLI-489
- Study Evaluating BLI-489 and Piperacillin in Healthy SubjectsCompletedPhase 1Wyeth is now a wholly owned subsidiary of PfizerNCT00894439Written as BLI-489/Piperacillin
Codes
What other systems call BLI-489 · ClinicalTrials.gg INT005417
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C539934 | BLI-489 | One source ClinicalTrials.gov |
| Wikidata | Q27287813 | bli-489 | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.